Marc Wilson
Fortune : 4 M $ au 30/06/2026
Fortune : 4 M $ au 30/06/2026
Marc J.
S.
Wilson formerly worked at Trius Therapeutics, Inc., as Accounting Director & Controller from 2010 to 2014, Cidara Therapeutics, Inc., as Chief Accounting Officer & Vice President from 2014 to 2018, and Crinetics Pharmaceuticals, Inc., as Chief Financial Officer from 2018 to 2025.
Mr. Wilson received his undergraduate degree from College of the Holy Cross (Massachusetts).
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/07/2026 | 105 237 ( 0,1 % ) | 4 M $ | 30/06/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Directeur Financier/CFO | 28/02/2025 |
| CIDARA THERAPEUTICS | Comptroller/Controller/Auditor | 03/01/2018 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial drugs for the treatment of infections | Comptroller/Controller/Auditor | 01/08/2014 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
College of the Holy Cross (Massachusetts)
College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial drugs for the treatment of infections | Health Technology |
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Engages in the discovery, development, and commercialization of novel anti-infectives | Health Technology |
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets therapeutics for endocrine-related diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national